Skip to main content

Trauma

9
Pipeline Programs
21
Companies
21
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
2
3
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

19 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
2 programs
1
Restrictive oxygenPhase 41 trial
Pulse oximeterN/A1 trial
Active Trials
NCT06256692Completed165Est. Sep 2024
NCT05146700Completed1,508Est. Oct 2024
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
Enoxaparin Sodium Injection 30 mg BIDPhase 41 trial
Active Trials
NCT02342444Unknown606Est. Mar 2025
GeneSys
GeneSysIndia - Hyderabad
1 program
1
intravenous fentanylPhase 41 trial
Active Trials
NCT00882960Unknown500Est. Apr 2012
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
1
1:1:1 Blood Transfusion RatioPhase 31 trial
Active Trials
NCT01545232Completed680Est. Dec 2013
Prothya Biosolutions
Prothya BiosolutionsBelgium - Brussels
1 program
1
C1-esterase inhibitorPhase 31 trial
Active Trials
NCT01275976Terminated11Est. Feb 2015
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
3 programs
1
Type AB plasmaPhase 21 trial
Flashback CRI T1 TabletN/A1 trial
Targeted NormoxiaN/A1 trial
Active Trials
NCT04911465Unknown300Est. Jun 2024
NCT03789396Completed572Est. Oct 2022
NCT01838863Terminated144Est. Apr 2017
CSL Seqirus
CSL SeqirusUK - Maidenhead
1 program
1
FibrinogenPhase 2
Healios
HealiosJapan - Tokyo
1 program
1
MultiStemPhase 21 trial
Active Trials
NCT04533464Recruiting156Est. Dec 2025
Baxter
BaxterCosta Rica - Cartago
1 program
1
open fracture reductionPhase 2
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
Psychophysiological fear conditioning and extinction taskN/A1 trial
Standard mHealth screeningN/A1 trial
Transfusion Using Stored Whole BloodN/A1 trial
Active Trials
NCT03778307Completed168Est. Jun 2025
NCT05430165Unknown4,500Est. Nov 2024
NCT02926274Completed330Est. Aug 2019
Martin Pharmaceuticals
1 program
AIS,START with films transferringN/A1 trial
Active Trials
NCT05358418Completed90Est. Sep 2023
Physical Sciences
Physical SciencesMA - Andover
1 program
Investigating Outcomes of Lower Limb TraumaN/A1 trial
Active Trials
NCT01691950Completed30Est. Apr 2014
Masimo
MasimoIRVINE, CA
1 program
Radical-7 Pulse CO-Oximeter and sensorN/A1 trial
Active Trials
NCT03123328Completed380Est. Mar 2017
Medtronic
MedtronicNJ - Phillipsburg
1 program
Registry AutoLog Lipid Removal and Blood Component CharacterizationN/A1 trial
Active Trials
NCT01565967Completed199Est. Mar 2013
Rhythm Pharmaceuticals
1 program
Registry AutoLog Lipid Removal and Blood Component CharacterizationN/A
Zimmer Biomet
Zimmer BiometFL - Jacksonville
1 program
VueLock™ Anterior Cervical PlateN/A1 trial
Active Trials
NCT00726128Completed371Est. Sep 2009
CSL Behring
CSL BehringIL - Bradley
1 program
FibrinogenPHASE_21 trial
Active Trials
NCT02344069Completed40Est. Apr 2017
Kuros Biosciences
Kuros BiosciencesSwitzerland - Schlieren
1 program
open fracture reductionPHASE_21 trial
Active Trials
NCT00533793Completed201Est. May 2011
Daiichi Sankyo
Daiichi SankyoChina - Shanghai
1 program
Transdermal PatchPHASE_31 trial
Active Trials
NCT02616068Completed242Est. Dec 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Nordic PharmaRestrictive oxygen
Oregon TherapeuticsEnoxaparin Sodium Injection 30 mg BID
GeneSysintravenous fentanyl
Daiichi SankyoTransdermal Patch
Defence Therapeutics1:1:1 Blood Transfusion Ratio
Prothya BiosolutionsC1-esterase inhibitor
HealiosMultiStem
CSL BehringFibrinogen
Colorado TherapeuticsType AB plasma
Kuros Biosciencesopen fracture reduction
Nordic PharmaPulse oximeter
Angeles TherapeuticsStandard mHealth screening
Martin PharmaceuticalsAIS,START with films transferring
Colorado TherapeuticsFlashback CRI T1 Tablet
Angeles TherapeuticsPsychophysiological fear conditioning and extinction task

Showing 15 of 21 trials with date data

Clinical Trials (21)

Total enrollment: 11,193 patients across 21 trials

NCT05146700Nordic PharmaRestrictive oxygen

Restrictive Vs. Liberal Oxygen in Trauma

Start: Dec 2021Est. completion: Oct 20241,508 patients
Phase 4Completed
NCT02342444Oregon TherapeuticsEnoxaparin Sodium Injection 30 mg BID

Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)

Start: Feb 2014Est. completion: Mar 2025606 patients
Phase 4Unknown
NCT00882960GeneSysintravenous fentanyl

Intranasal Fentanyl for Pain Management

Start: Apr 2009Est. completion: Apr 2012500 patients
Phase 4Unknown
NCT02616068Daiichi SankyoTransdermal Patch

Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma

Start: Oct 2015Est. completion: Dec 2016242 patients
Phase 3Completed
NCT01545232Defence Therapeutics1:1:1 Blood Transfusion Ratio

Pragmatic, Randomized Optimal Platelet and Plasma Ratios

Start: Aug 2012Est. completion: Dec 2013680 patients
Phase 3Completed
NCT01275976Prothya BiosolutionsC1-esterase inhibitor

Effect of C1-esterase Inhibitor on Systemic Inflammation in Trauma Patients With a Femur or Pelvic Fracture

Start: Apr 2012Est. completion: Feb 201511 patients
Phase 3Terminated
NCT04533464HealiosMultiStem

MultiStem® for Treatment of Trauma Induced Multiple Organ Failure/Systemic Inflammatory Response Syndrome

Start: Nov 2020Est. completion: Dec 2025156 patients
Phase 2Recruiting
NCT02344069CSL BehringFibrinogen

Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage

Start: Feb 2015Est. completion: Apr 201740 patients
Phase 2Completed
NCT01838863Colorado TherapeuticsType AB plasma

Control of Major Bleeding After Trauma Study

Start: Apr 2014Est. completion: Apr 2017144 patients
Phase 2Terminated
NCT00533793Kuros Biosciencesopen fracture reduction

Adjunctive Therapy to Treat Tibial Shaft Fractures

Start: Apr 2007Est. completion: May 2011201 patients
Phase 2Completed
NCT06256692Nordic PharmaPulse oximeter

Hypoxemia in the First 24 Hours After Trauma - an Observational Study

Start: Feb 2024Est. completion: Sep 2024165 patients
N/ACompleted
NCT05430165Angeles TherapeuticsStandard mHealth screening

Trauma Follow-Up Prediction (Project 2: Aim 1)

Start: May 2023Est. completion: Nov 20244,500 patients
N/AUnknown
NCT05358418Martin PharmaceuticalsAIS,START with films transferring

AIS and START Grade With Films Transferring in Disaster Management

Start: Dec 2022Est. completion: Sep 202390 patients
N/ACompleted
NCT04911465Colorado TherapeuticsFlashback CRI T1 Tablet

Continuous Assessment of Hemodynamic Compensation in Pediatric Trauma Patients

Start: May 2021Est. completion: Jun 2024300 patients
N/AUnknown
NCT03778307Angeles TherapeuticsPsychophysiological fear conditioning and extinction task

Key Dimensions of PTSD and ED

Start: Nov 2019Est. completion: Jun 2025168 patients
N/ACompleted
NCT03789396Colorado TherapeuticsTargeted Normoxia

Pilot Study of Targeted Normoxia in Critically Ill Trauma Patients

Start: Jan 2018Est. completion: Oct 2022572 patients
N/ACompleted
NCT02926274Angeles TherapeuticsTransfusion Using Stored Whole Blood

Transfusion Using Stored Whole Blood

Start: Oct 2017Est. completion: Aug 2019330 patients
N/ACompleted
NCT03123328MasimoRadical-7 Pulse CO-Oximeter and sensor

Evaluation of Non-Invasive Hemoglobin in Trauma Patients

Start: Jun 2016Est. completion: Mar 2017380 patients
N/ACompleted
NCT01691950Physical SciencesInvestigating Outcomes of Lower Limb Trauma

Investigating Outcomes of Lower Limb Trauma

Start: Apr 2012Est. completion: Apr 201430 patients
N/ACompleted
NCT01565967MedtronicRegistry AutoLog Lipid Removal and Blood Component Characterization

Registry AutoLog Lipid Removal and Blood Component Characterization

Start: Dec 2011Est. completion: Mar 2013199 patients
N/ACompleted
NCT00726128Zimmer BiometVueLock™ Anterior Cervical Plate

Patient Outcomes Evaluation of the EBI Vuelock™ Anterior Cervical Plate System

Start: Aug 1998Est. completion: Sep 2009371 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 11,193 patients
21 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.